BIO joins lawsuit against Medicare most-favored-nation drug pricing pilot

· Health · United States

Biotechnology industry group BIO has joined the legal fight against a Medicare pilot program that ties drug prices to those paid in peer countries, STAT reported. The model is a test of President Trump's most-favored-nation approach to drug pricing, under which U.S. prices would be benchmarked against lower prices abroad. STAT noted the program's practical impact is likely to be limited, but the litigation signals industry opposition to extending the approach. The suit follows prior legal challenges to the administration's drug-pricing agenda and adds to the uncertainty around how the pilot will be implemented.

Why it matters：Industry litigation against most-favored-nation pricing will shape whether the model can be expanded, affecting drugmakers' U.S. revenue expectations.

Key points

  • BIO joined the legal challenge to the Medicare pilot, per STAT.
  • The pilot benchmarks U.S. drug prices to peer countries.
  • STAT said the program's impact is likely to be limited.

Sources (original reporting)

More stories from this day